Nutritional Composition for Oligodendrocyte Myelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nutritional compositions fail to effectively promote oligodendrocyte survival and proliferation, leading to inadequate myelination and synapse development, which are crucial for neurological health and development, especially in infants and adults with neurodegenerative diseases.
Innovation Solution
A nutritional composition comprising exogenous inositol, a fat or lipid source, a protein or protein equivalent, and a carbohydrate, along with optional long-chain polyunsaturated fatty acids, phosphatidylethanolamines, sphingomyelin, alpha-lipoic acid, epigallocatechin gallate, and sulforaphane, which synergistically enhance neurological health and development by supporting oligodendrocyte precursor cell survival and myelination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nutritional compositions are used, then basic nutritional needs are met, but oligodendrocyte survival and proliferation are not effectively promoted, leading to inadequate myelination
Solution Approach 1:
The patent combines multiple nutrients (inositol at 12-40 mg/100 kcal, DHA, ARA, phosphatidylethanolamine, sphingomyelin, alpha-lipoic acid, epigallocatechin gallate, sulforaphane) into a composite nutritional formulation. This composite approach synergistically promotes oligodendrocyte survival, proliferation, and myelination more effectively than individual nutrients alone, resolving the contradiction between meeting basic nutritional needs and effectively supporting neurological development
Solution Approach 2:
The patent specifies precise parameter ranges for each nutrient component, particularly inositol at 12-40 mg/100 kcal, DHA at 10-50 mg/100 kcal, ARA at 10-50 mg/100 kcal, and other components within defined ranges. These optimized parameter combinations enhance myelination effectiveness while maintaining nutritional balance, addressing both reliability and adaptability requirements
2Productivity
If nutritional compositions aim to support rapid myelination in infants, then neurological development is improved, but the complexity of formulation increases
Solution Approach 1:
The patent defines specific parameter ranges for accelerating myelination: inositol at 12-40 mg/100 kcal, DHA at 10-50 mg/100 kcal, ARA at 10-50 mg/100 kcal, phosphatidylethanolamine at 5-20 mg/100 kcal, and other components within defined ranges. These optimized parameters enable rapid myelination while providing clear formulation guidelines that manage complexity through standardization
Solution Approach 2:
The nutritional composition serves multiple functions simultaneously: providing basic nutrition, promoting oligodendrocyte survival, enhancing proliferation, supporting myelination, and protecting against neurodegeneration. This multi-functionality achieves rapid myelination without proportionally increasing formulation complexity, as the same component组合 addresses multiple neurological development needs
3Reliability
If inositol is added to nutritional compositions to enhance neurological benefits, then oligodendrocyte survival and myelination improve, but the cost and formulation complexity increase
Solution Approach 1:
The patent specifies inositol at 12-40 mg/100 kcal as a core component with defined parameter ranges. This precise parameter specification ensures reliable oligodendrocyte survival support while managing formulation complexity through standardized dosing guidelines that simplify manufacturing and quality control
Solution Approach 2:
Inositol is integrated into a composite nutritional formulation containing DHA, ARA, phosphatidylethanolamine, sphingomyelin, alpha-lipoic acid, epigallocatechin gallate, and sulforaphane. This composite approach distributes the neurological support function across multiple components, reducing the burden on any single ingredient and managing overall formulation complexity while enhancing reliability
4Adaptability or versatility
If nutritional compositions are designed for both pediatric and adult subjects, then versatility is improved, but the difficulty of optimizing for different developmental stages increases
Solution Approach 1:
The nutritional composition is designed with universal applicability for both pediatric and adult subjects through carefully selected parameter ranges. The core components (inositol 12-40 mg/100 kcal, DHA 10-50 mg/100 kcal, ARA 10-50 mg/100 kcal, and others) provide neurological support that benefits oligodendrocyte health across different developmental stages, allowing a single formulation to serve multiple age groups without requiring complex stage-specific variations
Solution Approach 2:
The patent defines parameter ranges rather than fixed values, allowing flexibility in optimization for different age groups. The specified ranges (e.g., inositol 12-40 mg/100 kcal, DHA 10-50 mg/100 kcal) can be adjusted within boundaries to suit pediatric or adult needs, simplifying manufacturing by using a core formulation with adjustable parameters rather than completely different formulations for each age group
Data Source
AI summary
A method for enhancing neurological health and development in a subject involving administering to the subject a nutritional composition including no greater than about 7 g/100 kcal of a fat or lipid source; no greater than about 7 g/100 kcal of a protein or protein equivalent source; at least about 5 g/100 kcal of a carbohydrate; and at least about 9 mg/100 kcal of inositol, wherein the ratio of exogenous inositol to inherent inositol is at least 50:50.